Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia.
Astermark J, Ay C, Carvalho M, D'Oiron R, Moerloose P, Dolan G, Fontana P, Hermans C, Holme PA, Katsarou O, Kenet G, Klamroth R, Mancuso ME, Marquardt N, Núñez R, Pabinger I, Tait R, Valk PV. Astermark J, et al. Thromb Haemost. 2022 Jun;122(6):905-912. doi: 10.1055/a-1642-4067. Epub 2021 Nov 5. Thromb Haemost. 2022. PMID: 34507368
Treatment of the bleeding inhibitor patient.
Astermark J. Astermark J. Semin Thromb Hemost. 2003 Feb;29(1):77-86. doi: 10.1055/s-2003-37972. Semin Thromb Hemost. 2003. PMID: 12640569 Review.
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
Váradi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP, Turecek PL. Váradi K, et al. Among authors: astermark j. J Thromb Haemost. 2003 Nov;1(11):2374-80. doi: 10.1046/j.1538-7836.2003.00450.x. J Thromb Haemost. 2003. PMID: 14629472 Free article.
Overview of inhibitors.
Astermark J. Astermark J. Semin Hematol. 2006 Apr;43(2 Suppl 4):S3-7. doi: 10.1053/j.seminhematol.2006.03.006. Semin Hematol. 2006. PMID: 16690373 Review.
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Collins PW, et al. Among authors: astermark j. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20. J Thromb Haemost. 2009. PMID: 19143924 Free article. Clinical Trial.
European curriculum for thrombosis and haemostasis.
Astermark J, Negrier C, Hermans C, Holme PA, Klamroth R, Kotsi P, de Moerloose P, Pasi J, Rocino A, von Depka M, Windyga J, Ludlam CA; Interdisciplinary Working Group IDWG. Astermark J, et al. Haemophilia. 2009 Jan;15(1):337-44. doi: 10.1111/j.1365-2516.2008.01836.x. Haemophilia. 2009. PMID: 19149857 No abstract available.
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A.
Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Pavlova A, et al. Among authors: astermark j. J Thromb Haemost. 2009 Dec;7(12):2006-2015. doi: 10.1111/j.1538-7836.2009.03636.x. J Thromb Haemost. 2009. PMID: 19817985 Free article.
179 results